Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety risk

Still very preliminary drugs, that are risky and can only delay the full onset of the disease, but at the same time much better than the alternative.

Hopefully soon better options will become available thanks to the international companies that are also working to improve these treatments.

Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab.

Excellent to see these US companies and US global health authorities backing these medications and taking charge with their approval and distribution.

There is no such thing.

*For over 50 years, USAID’s global health programs have saved lives, *

https://www.usaid.gov/global-health

Health authorities are not "backing" medications. They approve them (or not).

*Alzheimer's drug gets FDA panel's backing,*

https://medicalxpress.com/news/2023-06-alzheimer-drug-fda-panel-stage.html

Otherwise, backing as in backing as written:

Alzheimer's drug gets **FDA panel's backing**,

A panel backing an internal decision of the FDA is not the same as the FDA backing the drug.

As your own source says

Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer's drug

They are not backing the drug, they are backing the decision to approve the drug.

The most promising development we've seen in Alzheimer's since the amyloid hypothesis was first proposed, I think. These initial drugs will have their dangers but, like the early rheumatoid arthritis drugs that caused liver disease, they will continue to get better and help patients and their families.